| | ||||
 |
|
|||
 >4x |
Module 63 -- Porins/transporters |
| General Properties | |
|---|---|
| Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module. | |
| Num gene sets: | 2 |
| Num genes: | 212 (see 2773 additional genes for this module) |
| Num experiments: | 596 (216 induced, 380 repressed) |
| Parent module: | None |
| Children modules: | None |
| Gene sets | |
|---|---|
| Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates. | |
| porin activity | |
| channel/pore class transporter activity | |
| Enriched clinical annotations | |||||||
|---|---|---|---|---|---|---|---|
| For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. | |||||||
| Clinical annotation | Category | P-value | Hits | Hits(%) | Module hits in category | Arrays in annotation | Arrays |
| Liver tissue (Liver cancer*) | Liver cancer* | 7.4e-26 | 72 | 33.3 | 216 | 187 | 1945 |
| Acute leukemia (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Cancer and cell line (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Cancer (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Hematologic cancer and cell line (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Hematologic cancer (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Hematologic samples and cell lines (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Leukemia (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Leukemia or leukemia cell line (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Monocytes (Leukemia*) | Leukemia* | 1.1e-24 | 80 | 21.1 | 379 | 141 | 1945 |
| Liver tissue, cancer or cell line (Liver cancer*) | Liver cancer* | 3.4e-24 | 72 | 33.3 | 216 | 197 | 1945 |
| Non-tumor liver tissue (Liver cancer) | Liver cancer | 4.2e-20 | 57 | 78.0 | 73 | 76 | 207 |
| Hepatitis infected liver (Liver cancer*) | Liver cancer* | 2.6e-17 | 55 | 25.4 | 216 | 156 | 1945 |
| Cancer and cell line (Liver cancer) | Liver cancer | 4.1e-17 | 65 | 98.4 | 66 | 126 | 207 |
| Cancer (Liver cancer) | Liver cancer | 1.5e-08 | 55 | 83.3 | 66 | 115 | 207 |
| Adenocarcinoma (Liver cancer) | Liver cancer | 5.2e-08 | 49 | 74.2 | 66 | 97 | 207 |
| Breast tissue or cancer (Breast cancer*) | Breast cancer* | 1.3e-07 | 33 | 15.2 | 216 | 118 | 1945 |
| Female hormonal tissue or cancer (Breast cancer*) | Breast cancer* | 1.3e-07 | 33 | 15.2 | 216 | 118 | 1945 |
| Cell line (Breast cancer) | Breast cancer | 1.7e-07 | 20 | 50 | 40 | 30 | 152 |
| B cells (Leukemia) | Leukemia | 2.6e-07 | 50 | 62.5 | 80 | 62 | 141 |
| Breast cancer cell line (Breast cancer) | Breast cancer | 4.0e-07 | 14 | 35 | 40 | 17 | 152 |
| Bone marrow (Leukemia) | Leukemia | 4.3e-07 | 23 | 28.7 | 80 | 23 | 141 |
| Cell line (B lymphoma) | B lymphoma | 8.1e-07 | 11 | 23.9 | 46 | 14 | 245 |
| Adenocarcinoma (Breast cancer*) | Breast cancer* | 1.4e-06 | 30 | 13.8 | 216 | 112 | 1945 |
| Breast cancer (Breast cancer*) | Breast cancer* | 1.4e-06 | 30 | 13.8 | 216 | 112 | 1945 |
| Cancer (Breast cancer*) | Breast cancer* | 1.4e-06 | 30 | 13.8 | 216 | 112 | 1945 |
| Female hormonal cancer (Breast cancer*) | Breast cancer* | 1.4e-06 | 30 | 13.8 | 216 | 112 | 1945 |
| Atypical teratoid/rhabdoid tumour - CNS and other origin (Neuro tumors) | Neuro tumors | 4.6e-06 | 7 | 63.6 | 11 | 10 | 90 |
| Liver cancer cell line (Liver cancer) | Liver cancer | 6.6e-06 | 10 | 15.1 | 66 | 10 | 207 |
| Female hormonal cancer cell line (Breast cancer) | Breast cancer | 6.7e-06 | 12 | 30 | 40 | 15 | 152 |
| Hepatocellular carcinoma (Liver cancer) | Liver cancer | 7.4e-06 | 48 | 72.7 | 66 | 104 | 207 |
| Activated B like DLBCL (B lymphoma) | B lymphoma | 7.5e-06 | 11 | 47.8 | 23 | 30 | 245 |
| Female hormonal tissue, cancer or cell line (Breast cancer*) | Breast cancer* | 1.1e-05 | 33 | 15.2 | 216 | 141 | 1945 |
| Breast tissue, cancer or cell line (Breast cancer*) | Breast cancer* | 1.2e-05 | 33 | 15.2 | 216 | 142 | 1945 |
| Female hormonal cancer or cell line (Breast cancer*) | Breast cancer* | 2.4e-05 | 30 | 13.8 | 216 | 127 | 1945 |
| Breast cancer or cell line (Breast cancer*) | Breast cancer* | 2.8e-05 | 30 | 13.8 | 216 | 128 | 1945 |
| Primary blood mononuclear cells (Leukemia) | Leukemia | 4.0e-05 | 20 | 25 | 80 | 21 | 141 |
| Cell line (Liver cancer) | Liver cancer | 5.3e-05 | 10 | 15.1 | 66 | 11 | 207 |
| Lung carcinoid (Lung cancer) | Lung cancer | 0.0001 | 12 | 20.3 | 59 | 20 | 276 |
| Liver tissue, cancer or cell line (Liver cancer*) | Liver cancer* | 0.0001 | 59 | 15.5 | 379 | 197 | 1945 |
| Invasive liver tumor (Liver cancer) | Liver cancer | 0.0002 | 22 | 33.3 | 66 | 38 | 207 |
| Cancer and cell line (Breast cancer*) | Breast cancer* | 0.0002 | 30 | 13.8 | 216 | 143 | 1945 |
| Enriched GO annotations | ||||||
|---|---|---|---|---|---|---|
| For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). | ||||||
| GO annotation | P-value | Hits | Hits(%) | Module genes | Genes in annotation | Genes |
| channel/pore class transporter activity | 9.8e-271 | 212 | 100 | 212 | 351 | 4566 |
| porin activity | 3.4e-156 | 145 | 68.3 | 212 | 235 | 4566 |
| receptor activity | 9.5e-113 | 165 | 77.8 | 212 | 582 | 4566 |
| integral to plasma membrane | 1.0e-71 | 137 | 64.6 | 212 | 612 | 4566 |
| alpha-type channel activity | 1.0e-67 | 74 | 34.9 | 212 | 133 | 4566 |
| transmembrane receptor activity | 6.2e-63 | 114 | 53.7 | 212 | 448 | 4566 |
| ion channel activity | 1.6e-60 | 66 | 31.1 | 212 | 117 | 4566 |
| transmembrane receptor protein kinase activity | 3.7e-37 | 40 | 18.8 | 212 | 68 | 4566 |
| ion transport | 1.5e-36 | 60 | 28.3 | 212 | 188 | 4566 |
| transmembrane receptor protein tyrosine kinase activity | 2.8e-36 | 38 | 17.9 | 212 | 62 | 4566 |
| signal transducer activity | 1.8e-33 | 127 | 59.9 | 212 | 1026 | 4566 |
| voltage-gated ion channel activity | 4.5e-33 | 35 | 16.5 | 212 | 58 | 4566 |
| ligand-gated ion channel activity | 5.9e-26 | 28 | 13.2 | 212 | 48 | 4566 |
| protein kinase activity | 9.2e-26 | 38 | 17.9 | 212 | 102 | 4566 |
| potassium ion transport | 4.7e-22 | 24 | 11.3 | 212 | 42 | 4566 |
| signal transduction | 5.8e-22 | 98 | 46.2 | 212 | 831 | 4566 |
| small molecule transport | 1.3e-21 | 37 | 17.4 | 212 | 121 | 4566 |
| extracellular ligand-gated ion channel activity | 8.2e-21 | 21 | 9.9 | 212 | 33 | 4566 |
| cell communication | 9.5e-19 | 105 | 49.5 | 212 | 1030 | 4566 |
| hematopoietin/interferon-class (D200-domain) cytokine receptor activity | 8.6e-18 | 21 | 9.9 | 212 | 42 | 4566 |
| potassium channel activity | 6.4e-17 | 17 | 8.0 | 212 | 27 | 4566 |
| voltage-gated potassium channel activity | 2.6e-16 | 15 | 7.0 | 212 | 21 | 4566 |
| cation transport | 7.4e-16 | 31 | 14.6 | 212 | 120 | 4566 |
| excitatory extracellular ligand-gated ion channel activity | 1.3e-15 | 14 | 6.6 | 212 | 19 | 4566 |
| protein tyrosine kinase activity | 6.0e-15 | 30 | 14.1 | 212 | 120 | 4566 |
| cell surface receptor linked signal transduction | 7.7e-15 | 44 | 20.7 | 212 | 259 | 4566 |
| transmembrane receptor protein tyrosine kinase signaling pathway | 3.0e-14 | 20 | 9.4 | 212 | 52 | 4566 |
| monovalent inorganic cation transport | 3.3e-14 | 24 | 11.3 | 212 | 79 | 4566 |
| synaptic transmission | 1.3e-13 | 28 | 13.2 | 212 | 116 | 4566 |
| eye photoreceptor cell fate commitment | 1.3e-13 | 17 | 8.0 | 212 | 38 | 4566 |
| compound eye morphogenesis (sensu Drosophila) | 6.4e-13 | 17 | 8.0 | 212 | 41 | 4566 |
| post-embryonic morphogenesis | 6.4e-13 | 17 | 8.0 | 212 | 41 | 4566 |
| post-embryonic development | 1.0e-12 | 17 | 8.0 | 212 | 42 | 4566 |
| voltage-gated potassium channel complex | 1.0e-12 | 12 | 5.6 | 212 | 18 | 4566 |
| vesicle-mediated transport | 3.7e-11 | 33 | 15.5 | 212 | 196 | 4566 |
| neurotransmitter receptor activity | 1.9e-10 | 11 | 5.1 | 212 | 20 | 4566 |
| chloride transport | 2.2e-10 | 12 | 5.6 | 212 | 25 | 4566 |
| GABA-A receptor activity | 5.5e-10 | 10 | 4.7 | 212 | 17 | 4566 |
| Fc receptor activity | 7.8e-10 | 8 | 3.7 | 212 | 10 | 4566 |
| nicotinic acetylcholine-activated cation-selective channel activity | 7.8e-10 | 8 | 3.7 | 212 | 10 | 4566 |
| response to extracellular stimulus | 8.1e-10 | 54 | 25.4 | 212 | 500 | 4566 |
| interleukin receptor activity | 1.1e-09 | 12 | 5.6 | 212 | 28 | 4566 |
| membrane fraction | 2.4e-09 | 39 | 18.3 | 212 | 304 | 4566 |
| integrin complex | 4.6e-09 | 10 | 4.7 | 212 | 20 | 4566 |
| inorganic anion transport | 4.7e-09 | 12 | 5.6 | 212 | 31 | 4566 |
| response to stress | 1.0e-08 | 70 | 33.0 | 212 | 792 | 4566 |
| acetylcholine receptor activity | 1.4e-08 | 7 | 3.3 | 212 | 9 | 4566 |
| nicotinic acetylcholine-gated receptor-channel complex | 1.4e-08 | 7 | 3.3 | 212 | 9 | 4566 |
| integrin-mediated signaling pathway | 2.5e-08 | 10 | 4.7 | 212 | 23 | 4566 |
| anion transport | 3.4e-08 | 12 | 5.6 | 212 | 36 | 4566 |
| cell adhesion receptor activity | 4.1e-08 | 10 | 4.7 | 212 | 24 | 4566 |
| immunoglobulin receptor activity | 6.6e-08 | 10 | 4.7 | 212 | 25 | 4566 |
| interleukin binding | 6.6e-08 | 10 | 4.7 | 212 | 25 | 4566 |
| immune response | 1.4e-07 | 47 | 22.1 | 212 | 469 | 4566 |
| actin filament-based movement | 1.7e-07 | 12 | 5.6 | 212 | 41 | 4566 |
| cell-matrix adhesion | 3.4e-07 | 10 | 4.7 | 212 | 29 | 4566 |
| protein amino acid phosphorylation | 5.2e-07 | 29 | 13.6 | 212 | 230 | 4566 |
| transmembrane receptor protein phosphatase activity | 5.7e-07 | 7 | 3.3 | 212 | 13 | 4566 |
| actin filament-based process | 9.1e-07 | 12 | 5.6 | 212 | 47 | 4566 |
| response to biotic stimulus | 1.2e-06 | 53 | 25 | 212 | 600 | 4566 |
| ephrin receptor activity | 3.5e-06 | 6 | 2.8 | 212 | 11 | 4566 |
| gap junction | 4.0e-06 | 5 | 2.3 | 212 | 7 | 4566 |
| gap-junction forming channel activity | 4.0e-06 | 5 | 2.3 | 212 | 7 | 4566 |
| delayed rectifier potassium channel activity | 4.5e-06 | 4 | 1.8 | 212 | 4 | 4566 |
| amine receptor activity | 5.1e-06 | 9 | 4.2 | 212 | 30 | 4566 |
| excretion | 5.1e-06 | 9 | 4.2 | 212 | 30 | 4566 |
| muscle contraction | 7.4e-06 | 14 | 6.6 | 212 | 76 | 4566 |
| NGF/TNF (6 C-domain) receptor activity | 2.1e-05 | 4 | 1.8 | 212 | 5 | 4566 |
| GPI-anchored membrane-bound receptor | 2.2e-05 | 5 | 2.3 | 212 | 9 | 4566 |
| inward rectifier potassium channel activity | 2.2e-05 | 5 | 2.3 | 212 | 9 | 4566 |
| voltage-gated chloride channel activity | 2.2e-05 | 5 | 2.3 | 212 | 9 | 4566 |
| calcium channel activity | 6.2e-05 | 4 | 1.8 | 212 | 6 | 4566 |
| defense/immunity protein activity | 6.5e-05 | 15 | 7.0 | 212 | 103 | 4566 |
| G-protein coupled receptor activity | 9.4e-05 | 20 | 9.4 | 212 | 170 | 4566 |
| rhodopsin-like receptor activity | 0.0001 | 18 | 8.4 | 212 | 147 | 4566 |
| two-component signal transduction system (phosphorelay) | 0.0001 | 7 | 3.3 | 212 | 26 | 4566 |
| Visual display | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets. | |||||||||
| You can also view the images within GeneXPress by loading the module gxp file file. | |||||||||
| Note: Since there are 596 experiments, this image does not display the individual experiment names, but rather condenses each experiment to a single pixel without displaying its name. You can fully view the image for this module within GeneXPress, by loading any of the four files mentioned in the line above | |||||||||
|
|||||||||
